Immunovant, Inc. (IMVT) stock
IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$33.17−0.04 (-0.12%)
Close on Nov 18, 2026Market cap $6.85BP/E –Yield –
Immunovant shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Immunovant's shares outstanding was 206M at Jun 30, 2026. For fiscal 2026 it was 182M, up 20.4% from the year before. The highest annual figure on record is 182M in fiscal 2026.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | 182M | +20.4% |
| FY2025 | Mar 31, 2025 | 152M | +9.8% |
| FY2024 | Mar 31, 2024 | 138M | +12.2% |
| FY2023 | Mar 31, 2023 | 123M | +12.2% |
| FY2022 | Mar 31, 2022 | 110M | +25.0% |
| FY2021 | Mar 31, 2021 | 88M | +103.1% |
| FY2020 | Mar 31, 2020 | 43M | +94.8% |
| FY2019 | Mar 31, 2019 | 22M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | 206M | +20.3% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | 203M | +22.1% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | 182M | +23.5% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | 174M | +18.6% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | 171M | +17.0% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | 167M | +14.4% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | 147M | +1.7% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | 146M | +11.7% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | 146M | +11.9% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | 146M | +11.8% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | 145M | +12.4% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | 131M | +12.5% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | 131M | +12.0% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | 130M | +12.0% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | 129M | +11.8% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | 117M | +6.9% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | 117M | +19.0% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | 116M | +19.0% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | 115M | +17.5% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | 109M | +29.3% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | 98M | +38.3% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | 98M | +71.5% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | 98M | +153.7% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | 84M | +912.2% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | 71M | +92.8% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | 57M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | 39M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | 8M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | 37M | – |
See a number that looks wrong?